This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
THE SPRINGTIME PARTNERING EVENT
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Convert Pharmaceuticals

Profile

Convert Pharmaceuticals is a drug development company building a proprietary drug pipeline exploiting tumour hypoxia for therapeutic benefit. Convert’s lead product, CP-506 is a hypoxia activated prodrug - HAP. The company combines proprietary insights in the tumour hypoxia with expertise in drug and biomarker development to develop effective and well-tolerated HAPs. Convert has an ongoing phase I-IIa trial, is supported by the EIC (€2.5M), and has acquired the IP of an additional HAP.